A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer by unknown
1 3
Int J Clin Oncol (2016) 21:773–782
DOI 10.1007/s10147-016-0952-6
ORIGINAL ARTICLE
A multicenter phase I/II study of enzalutamide in Japanese 
patients with castration‑resistant prostate cancer
Hideyuki Akaza1 · Hirotsugu Uemura2 · Taiji Tsukamoto3 · Seiichiro Ozono4 · 
Osamu Ogawa5 · Hideki Sakai6 · Mototsugu Oya7 · Mikio Namiki8 · 
Satoshi Fukasawa9 · Akito Yamaguchi10 · Hiroji Uemura11 · Yasuo Ohashi12 · 
Hideki Maeda13 · Atsushi Saito13 · Kentaro Takeda13 · Seiji Naito10 
Received: 23 November 2015 / Accepted: 7 January 2016 / Published online: 21 January 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
were enrolled into phase II; receiving long-term adminis-
tration of enzalutamide 160 mg/day.
Results Nine and 38 patients were enrolled in phase I and 
II, respectively. During phase I, enzalutamide was well tol-
erated in each cohort; PK parameters were similar to those 
of non-Japanese populations in other studies. By week 12, 
overall response rate was 5.3 % and clinical benefit rate 
was 47.4 %. Prostate-specific antigen response rate (≥50 % 
reduction from baseline) was 28.9 %. Treatment-emergent 
adverse events reported in >20 % of patients in phase II 
were decreased weight, decreased appetite and constipa-
tion. No seizures were observed.
Conclusion Enzalutamide at 160 mg/day was well 
tolerated, with PK and safety profiles similar to the 
Abstract 
Background The safety, tolerability, pharmacokinetics 
(PK) and anti-tumor activity of enzalutamide were inves-
tigated in patients with castration-resistant prostate cancer 
(CRPC) in Japan through a multicenter phase I/II study.
Methods In phase I, patients with progressive metastatic 
CRPC received single, then multiple, ascending doses of 
enzalutamide 80, 160 or 240 mg/day. After assessment of 
tolerability at multiple doses of 160 mg/day for 4 weeks, 
post-docetaxel patients with CRPC and measurable disease 
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non-Japanese population. Anti-tumor activity was observed 
in post-docetaxel Japanese patients with metastatic CRPC. 
Apparent differences in anti-tumor activity compared with 
the AFFIRM study (a phase III trial in a diverse population 
of patients with CRPC post-docetaxel) may be attributed 
to differences in treatment history prior to starting enzalu-
tamide. Particularly in Japan, the influence of sequence in 
hormone treatments, including combined androgen block-
ade therapy, should be considered.
 Trial registration: ClinicalTrials.gov NCT01284920.
Keywords Androgen receptor inhibitor · Enzalutamide · 
Metastatic castration-resistant prostate cancer
Introduction
As prostate cancer growth is dependent on androgens, 
androgen deprivation therapy (ADT), which includes sur-
gical castration or medical therapy with gonadotropin-
releasing hormone (GnRH) agonists or GnRH antago-
nists, is standard therapy for patients with metastatic 
prostate cancer recurrence after definitive therapy, or 
inoperable prostate cancer. In Japan, it is common prac-
tice in primary ADT to use androgen blockade combined 
with bicalutamide, a non-steroidal anti-androgen [1–4]. 
Progression of the disease despite castrate levels of tes-
tosterone under primary ADT is considered castration-
resistant prostate cancer (CRPC) [5] and it generally rep-
resents a transition to the lethal state of the disease. CRPC 
is frequently treated with hormone therapy alternating 
with anti-androgens, low dose steroids or estrogenic com-
pounds [6]. However, prolonged survival of patients with 
CRPC by these secondary hormonal treatments is not con-
firmed [7]. Until early 2014, docetaxel plus prednisone 
were the only approved drugs for patients with advanced 
CRPC in Japan [8, 9].
Recent treatment options that have demonstrated a 
survival improvement in patients with metastatic CRPC 
include cabazitaxel plus prednisone [10] and abiraterone 
plus prednisone [11, 12]. Enzalutamide [13, 14], sipuleu-
cel-T [15] and radium Ra 223 dichloride [16] have also 
been approved for use in several countries.
Enzalutamide is a novel androgen receptor inhibitor that 
significantly prolongs survival of men with CRPC regard-
less of prior docetaxel therapy [13]. Enzalutamide inhibits 
multiple steps in the androgen receptor signaling pathway 
and is devoid of agonist activity in preclinical models [17]. 
Preclinical pharmacology studies have demonstrated that 
enzalutamide competitively inhibits androgen-induced 
receptor activation, nuclear translocation of activated 
androgen receptors, and the association of the activated 
androgen receptor with chromatin, even in the setting of 
androgen receptor over-expression and in prostate cancer 
cells resistant to anti-androgens [17].
The efficacy of enzalutamide was evaluated in two mul-
tinational phase III studies in men with metastatic CRPC; 
AFFIRM and PREVAIL. The AFFIRM trial showed over-
all survival (OS) benefit of enzalutamide in post-docetaxel 
patients with metastatic CRPC versus placebo. Median sur-
vival was 18.4 months with enzalutamide and 13.6 months 
with placebo [hazard ratio 0.63; 95 % confidence interval 
(CI) 0.53–0.75; p < 0.001] [14]. The PREVAIL trial con-
firmed clinical benefit of enzalutamide in chemotherapy-
naïve patients with metastatic CRPC. The hazard ratio of 
OS and radiographic progression-free survival (rPFS) were 
0.71 (95 % CI 0.60–0.84; p < 0.001) and 0.19 (95 % CI 
0.15–0.23; p < 0.001), respectively [13]. Median OS was 
32.4 months with enzalutamide and 30.2 months with pla-
cebo. Median rPFS was not reached with enzalutamide and 
was 3.9 months with placebo [13].
The present phase I/II clinical study evaluated the safety, 
tolerability and pharmacokinetics (PK) of enzalutamide 
in patients with CRPC and the anti-tumor activity and 
safety of enzalutamide in Japanese post-docetaxel patients 
with CRPC to provide supporting data for the regulatory 
approval of enzalutamide in Japan.
Patients and methods
Study design
This was a multicenter, open-label, uncontrolled study of 
orally administered enzalutamide, involving two phases 
(http://ClinicalTrials.gov NCT01284920). Phase I involved 
dose escalation in patients with CRPC. Phase II involved 
dose expansion in post-docetaxel patients with CRPC.
All participating sites obtained approval for conducting 
the study by their institutional review boards. The study 
was conducted in accordance with the Declaration of Hel-
sinki, Good Clinical Practice Guidelines and the Pharma-
ceutical Affairs Law in Japan. All patients provided written 
informed consent to participate in the study.
In phase I, patients received a single dose of enzaluta-
mide (80, 160 or 240 mg/day) and blood samples for PK 
analysis were collected over 7 days. Subsequently, patients 
received multiple doses of enzalutamide at the same dos-
age levels as in the single-dose period. Tolerability was 
evaluated 29 days after initiation of repeat dosing by an 
independent data monitoring committee. Patients who 
received 240 mg in the single-dose period subsequently 
received multiple doses of 160 mg/day (the recommended 
dose in the AFFIRM study [12]). Following the evaluation 
of enzalutamide tolerability and PK parameters after sin-
gle and multiple doses at 160 mg in phase I, an open-label, 
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uncontrolled phase II study was initiated to evaluate the 
efficacy, safety and PK in patients receiving enzalutamide 
160 mg/day. The study design was discussed with the Phar-
maceuticals and Medicine Devices Agency from a per-
spective of regulatory approval of enzalutamide in Japan. 
Consequently, overall response rate was selected to be the 
primary outcome variable in this study, thereby requiring 
enrolment of patients with measureable disease into the 
study.
Patients
Patients with metastatic CRPC who had disease pro-
gression while on castration therapy were eligible for 
participation. Patients had to have received ADT with a 
GnRH analogue or a bilateral orchiectomy with serum 
testosterone level maintained within castration level 
(≤50 ng/dL).
The criteria used to define disease progression for trial 
entry are available in the Online Resource. Eligible patients 
had Eastern Cooperative Oncology Group performance 
status of 0 or 1 (or 2 if only due to metastatic bone pain 
at the screening). Post-chemotherapy patients had to have 
received prior chemotherapy with docetaxel and no more 
than two prior chemotherapy regimens. In particular for 
phase II, patients had to have measurable lesions as deter-
mined by response evaluation criteria for solid tumors 
(RECIST) guidelines.
Exclusion criteria were history of seizure (including any 
febrile seizure, loss of consciousness or transient ischemic 
attack within 12 months prior to initiation of study drug) or 
any condition that may predispose to seizure. The complete 
list of exclusion criteria is available in the Online Resource.
Assessments
The primary outcome in anti-tumor activity in phase 
II was best overall response by 12 weeks; defined by 
RECIST guidelines as complete response (CR) or partial 
response (PR) and assessed by an investigator. Confirma-
tion of CR or PR was required by a subsequent scan at least 
4 weeks later. When the investigator confirmed CR or PR, 
the assessment was finally evaluated by an independent 
RECIST assessment committee. Measurements had to meet 
the stable disease criteria by day 85 for determination of 
stable disease. Radiographic imaging for the target region 
was conducted at the screening visit, on day 29, day 57 and 
day 85, and at each subsequent visit every 84 days. Bone 
scans were examined at the screening visit and at each 
84-day visit.
The secondary endpoint was prostate-specific anti-
gen (PSA) response rate (proportion of subjects with 
≥50 % decline in serum PSA from baseline). Serum PSA 
measurements were conducted at the screening visit and at 
each subsequent visit every 28 days.
Safety was evaluated from the start of study treatment to 
30 days after completion of the study treatment. All adverse 
events (AEs) were recorded using the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
(NCI CTCAE), version 4.0, and Medical Dictionary for 
Regulatory Activities (MedDRA), version 14.1. Laboratory 
values, vital signs, body weight and 12-lead echocardio-
grams were assessed at predefined time points.
Blood samples were collected at predefined time points 
in phase I and phase II. Plasma concentrations of enzaluta-
mide and its active metabolite, N-desmethyl enzalutamide, 
were determined by a validated bioanalytical method based 
on liquid chromatography combined with mass spectrom-
etry [18]. PK parameters were estimated by non-compart-
mental methods in WinNonlin® (Pharsight Corp., Palo Alto, 
CA, USA) and included maximum plasma concentration 
(Cmax) and area under the plasma concentration–time curve 
from time 0 to infinity (AUC∞). To investigate potential PK 
differences between Japanese and non-Japanese patients, 
the PK data were compared with PK data from AFFIRM.
Statistical analysis
The number and percentage of patients with a best overall 
response by day 85 and two-sided 90 and 95 % Clopper–
Pearson CIs were used in the primary analysis. A waterfall 
plot of maximum percent change from baseline of serum 
PSA was created. The number and percentage of patients 
with best PSA response at time of nadir were summarized. 
All data processing, summarization and analyses were per-
formed using SAS Drug Development, version 3.4, and PC-
SAS, version 9.1.3. All analyses were performed by the spon-
sor using data obtained by the cut-off date of 12 July 2012.
Post hoc analysis
An additional post hoc exploratory analysis was conducted 
to further compare enzalutamide anti-tumor activity in Jap-
anese patients with non-Japanese patients with measurable 
disease from the AFFIRM study. The best overall response 
by number of prior hormonal therapy lines, and defined by 
RECIST and PSA response rate, was calculated.
Results
Patients
In phase I, three patients were assigned to each of the 80, 
160 and 240 mg groups. The median duration of exposure 
in each group was 584.0, 171.0 and 252.0 days, respectively. 
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Thirty-eight post-docetaxel patients with CRPC and measur-
able disease as defined by RECIST were enrolled into phase 
II at a dose of 160 mg/day. Median duration of exposure was 
121 days. No remarkable differences were observed in the 
demographic and clinical baseline characteristics between 
the phase I and phase II study populations (Table 1). Patients 
in phase II were heavily pretreated, with >90 % having had 
≥4 prior hormonal treatments (Table 2). Eight of 38 patients 
(21.1 %) in phase II discontinued due to AEs. Of these, five 
patients withdrew due to disease progression (Table 3). All 
Table 1  Summary of demographics and other baseline characteristics
Demographic/characteristic Phase I (N = 9) Phase II (N = 38)
Age (years)
 Median 73.0 71.5
 Min–max 62–86 50–85
Height (cm)
 Median 166.0 165.7
 Min–max 156.2–174.4 153.4–181.0
Weight (kg)
 Median 71.2 65.7
 Min–max 49.2–88.9 49.2–93.0
ECOG PSa
 Grade 0 8 (88.9) 25 (65.8)
 Grade 1 1 (11.1) 13 (34.2)
Total Gleason scoreb at initial diagnosisa
 Low, 2–4 0 0
 Medium, 5–7 0 8 (21.1)
 High, 8–10 9 (100.0) 29 (76.3)
 Unknown 0 1 (2.6)
Clinical tumor stage (T)c at initial diagnosisa
 TX 1 (11.1) 1 (2.6)
 T0 0 0
 T1 0 0
 T2 1 (11.1) 10 (26.3)
 T3 6 (66.7) 16 (42.1)
 T4 1 (11.1) 10 (26.3)
 Unknown 0 1 (2.6)
Clinical lymph node stage at initial diagnosisa
 NX 2 (22.2) 1 (2.6)
 N0 3 (33.3) 14 (36.8)
 N1 4 (44.4) 22 (57.9)
 Unknown 0 1 (2.6)
Distant metastasis (M)c at initial diagnosisb
 MX 0 1 (2.6)
 M0 3 (33.3) 17 (44.7)
 M1 6 (66.7) 19 (50.0)
 Unknown 0 1 (2.6)
Number of bone metastases
 0 3 (33.3) 8 (21.1)
 1 1 (11.1) 1 (2.6)
 2–4 1 (11.1) 6 (15.8)
 5–9 0 7 (18.4)
 ≥10 4 (44.4) 16 (42.1)
Anti-androgen withdrawal syndromea
 Yes 0 4 (10.5)
Stage of prostate cancera,b
 Localized 1 (11.1) 6 (15.8)
 Locally advanced 2 (22.2) 11 (28.9)
 Metastatic 6 (66.7) 19 (50.0)
 Not classifiable 0 2 (5.3)
ECOG PS Eastern Cooperative Oncology Group performance status, 
PSA prostate-specific antigen, SD standard deviation
a Number (%) of patients
b Gleason [27]
c Classified using the TNM classification [28] as follows: localized, 
T1/2 and (NX or N0) and M0; locally advanced, T3/4 and (NX or 
N0) and M0 or N1 and M0; metastatic, M1; Not classifiable, others
Table 1  continued
Demographic/characteristic Phase I (N = 9) Phase II (N = 38)
PSA at baseline (ng/mL)
 Mean (SD) 634.82 (1403.52) 174.94 (307.97)
 Median 21.60 65.80
Duration of disease at screening (months)
 Mean (SD) 47.36 (22.23) 63.11 (38.15)
 Median 39.93 52.83
Table 2  Prior treatments for prostate cancer in phase II
GnRH gonadotropin-releasing hormone
a Sum of prior hormonal treatment agents including castration therapy
Parameter Category/statistic Phase II (N = 38)
Cancer treatment history,  
radiation
Yes 19 (50.0 %)
Cancer treatment history, 
procedure
Yes 6 (15.8 %)
Quantity of prior hormone 
therapy linesa
3 3 (7.9 %)
4 5 (13.2 %)
5 13 (34.2 %)
6 11 (28.9 %)
≥7 6 (15.8 %)
Typical prior hormone therapy, 
other than GnRH analogue
Bicalutamide 38 (100.0 %)
Flutamide 29 (76.3 %)
Estramustine 30 (78.9 %)
Docetaxel 38 (100 %)
Number of prior chemotherapy 
regimens
1 8 (21.1 %)
2 30 (78.9 %)
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patients had received complete androgen blockade (CAB) 
therapy with bicalutamide soon after their initial diagnosis of 
prostate cancer. Overall, 42.1 % had >10 bone metastases and 
all patients had measurable disease by RECIST (Table 1).
Anti‑tumor activity
Response
The best overall response rate (CR and PR) by day 85, as 
evaluated by the RECIST assessment committee and inves-
tigators, was seen in 5.3 % of patients (two out of 38; 95 % 
CI 0.6–17.7 %; 90 % CI 0.9–15.7 %). The best overall dis-
ease control rate (CR plus PR plus stable disease) by day 
85 was 47.4 % of patients (18 out of 38; 95 % CI 31.0–
64.2 %; 90 % CI 33.3–61.8 %) (Table 4). The rate with 
which the sum of diameters of target lesions was reduced 
by ≥30 % was 18.4 % (7 out of 38 patients).
PSA
Eleven out of 38 patients in phase II (28.9 %; 95 % CI 
15.4–45.9 %) had a ≥50 % decrease in PSA levels at the 
time of nadir, as compared with baseline (Fig. 1; Table 5).
Safety
The most frequent treatment-emergent AEs (TEAEs) 
with an incidence of ≥20 % across both phases were 
weight decrease (36.2 %), decreased appetite (27.7 %) 
and constipation (25.5 %) (Table 6). Of the adverse 
drug reactions reported in ≥10 % of patients, those con-
sidered to be related to the study drug were hyperten-
sion (14.9 %), constipation (14.9 %), fatigue (12.8 %), 
decreased appetite (12.8 %), weight decrease (10.6 %) 
and electrocardiogram QT prolonged (10.6 %). None 
Table 3  Primary reasons for discontinuation
Category and reason Phase I (N = 9) Phase II (N = 38)
Discontinuation in multiple-dose period (early termination), n (%)
 Adverse event 0 5 (13.2)
 Worsening of disease 1 (11.1) 5 (13.2)
 Withdrawal by subject 0 2 (5.3)
Discontinuation in overall study, n (%)
 Adverse event 0 8 (21.1)
 Worsening of disease 5 (55.6) 18 (47.4)
 Withdrawal by subject 0 2 (5.3)
Table 4  Best overall responses by day 85
Tumor response (overall response) for each patient was assessed 
by the investigator and subsequently evaluated by an independent 
RECIST assessment committee (when the investigator assessed that a 
patient had been accomplished CR or PR)
CR complete response, PD progressive disease, PR partial response
a When there were evaluation data from both the RECIST committee 
and investigator, RECIST assessment committee data were adopted
b Based on exact binomial confidence interval (Clopper–Pearson)
Best overall response Evaluation by RECIST assess-
ment committee and investigatora 
(N = 38)
CR, n 0
PR, n (%) 2 (5.3)
Stable disease, n (%) 16 (42.1)
PD, n (%) 16 (42.1)
Not evaluated 4 (10.5)
CR or PR, n (%) (response rate) 2 (5.3)
 95 % CIb 0.6–17.7 %
 90 % CIb 0.9–15.7 %
CR or PR or stable disease, n (%) 
(disease control rate)
18 (47.4)
 95 % CIb 31.0–64.2 %
 90 % CIb 33.3–61.8 %
Fig. 1  Waterfall plot of maxi-
mum percent change from base-
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of the TEAEs resulted in death and no seizures were 
reported. The most common serious TEAE was cancer 
pain (N = 3) (Table 7).
Pharmacokinetics
Enzalutamide was absorbed rapidly after oral administra-
tion in Japanese patients and the PK was dose-proportional 
after a single dose ranging from 80 to 240 mg (Fig. 2). 
The PK profile of a single dose of enzalutamide in Japa-
nese patients was similar to that of non-Japanese patient 
data from the first enzalutamide study in humans (phase I/
II study; http://ClinicalTrials.gov NCT00510718) (Fig. 2) 
[19]. PK profiles of the sum of enzalutamide plus its 
active metabolite in plasma were similar between Japanese 
patients from the current study and non-Japanese popula-
tions from AFFIRM (Fig. 3).
Table 5  Best PSA response at time of nadir
CI confidence interval, PSA prostate-specific antigen
Response 160 mg/day (N = 38)
Decline from baseline, patients, n (%) 
≥ 30 % 15 (39.5)
 95 % CI 24.0–56.6 %
≥50 % 11 (28.9)
 95 % CI 15.4–45.9 %
≥90 % 4 (10.5)
 95 % CI 2.9–24.8 %
Table 6  Common adverse events (reported in at least 10 % of patients in total)
Number of patients (%)
MedDRA Medical Dictionary for Regulatory Activities
MedDRA, version 14.1,  
preferred term
All adverse events Adverse events considered to be related to  
study drug
Phase I (N = 9) Phase II (N = 38) Total (N = 47) Phase I (N = 9) Phase II (N = 38) Total (N = 47)
Overall 9 (100.0) 36 (94.7) 45 (95.7) 7 (77.8) 24 (63.2) 31 (66.0)
Weight decreased 1 (11.1) 16 (42.1) 17 (36.2) 0 5 (13.2) 5 (10.6)
Decreased appetite 3 (33.3) 10 (26.3) 13 (27.7) 2 (22.2) 4 (10.5) 6 (12.8)
Constipation 2 (22.2) 10 (26.3) 12 (25.5) 1 (11.1) 6 (15.8) 7 (14.9)
Hypertension 3 (33.3) 6 (15.8) 9 (19.1) 3 (33.3) 4 (10.5) 7 (14.9)
Cancer pain 1 (11.1) 8 (21.1) 9 (19.1) 0 1 (2.6) 1 (2.1)
Nausea 4 (44.4) 5 (13.2) 9 (19.1) 1 (11.1) 2 (5.3) 3 (6.4)
Electrocardiogram QT prolonged 0 6 (15.8) 6 (12.8) 0 5 (13.2) 5 (10.6)
Fatigue 2 (22.2) 4 (10.5) 6 (12.8) 2 (22.2) 4 (10.5) 6 (12.8)
Nasopharyngitis 1 (11.1) 5 (13.2) 6 (12.8) 0 0 0
Pyrexia 1 (11.1) 4 (10.5) 5 (10.6) 1 (11.1) 0 1 (2.1)
Somnolence 0 5 (13.2) 5 (10.6) 0 1 (2.6) 1 (2.1)
Rash 0 5 (13.2) 5 (10.6) 0 1 (2.6) 1 (2.1)
Table 7  Serious treatment-
emergent adverse events (with 
an incidence of ≥2 events in  
the study)
Number of patients (%)
MedDRA Medical Dictionary for Regulatory Activities
a In phase I, safety data from single doses (80, 160 and 240 mg) and multiple doses (80 and 160 mg) are 
included. All patients in the 240 mg group received enzalutamide at a dose of 160 mg after single dosing
MedDRA, version 14.1, preferred term Phase I totala (N = 9) Phase II 160 mg (N = 38)
Overall 2 (22.2) 13 (34.2)
Cancer pain 1 (11.1) 2 (5.3)
Anemia 0 2 (5.3)
Disseminated intravascular coagulation 0 2 (5.3)
General physical health deterioration 0 2 (5.3)
Cellulitis 0 2 (5.3)
Tumor pain 0 2 (5.3)
Bladder tamponade 0 2 (5.3)
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Post hoc analysis
An exploratory post hoc analysis compared the sub-
group of non-Japanese patients with measurable disease 
from AFFIRM [N = 446 out of 800 enzalutamide-treated 
patients (cut-off date: 25 September 2011)] and Japanese 
patients from the current study (N = 38). The quantity of 
prior hormonal therapy lines used as prostate cancer treat-
ment in the two studies, which excluded medical or surgi-
cal castration therapy, is available in the Online Resource 
in Table S1. While approximately 90 % of patients in the 
AFFIRM study had received ≤2 hormonal therapy lines, 
approximately 90 % of patients in the current study had 
received ≥3 hormonal therapy lines. Best overall response 
rate, by RECIST, and PSA response rate for each amount 
of prior hormonal therapy lines are available in the Online 
Resource in Table S2 and Table S3, respectively.
Discussion
In patients who receive primary androgen deprivation 
therapy, the proportion of patients with high risk and/
or advanced prostate cancer is higher in Japan than in the 
United States [2]. A randomized, controlled study of pri-
mary ADT by CAB with chemical castration by GnRH 
agonist and bicalutamide 80 mg in Japanese patients 
showed significant prolongation of OS compared with 
chemical castration alone [20]. Based on this result, CAB 
is used in Japan as a standard initial therapy for high-risk or 
progressive prostate cancer [2, 4].
Results from this first clinical study of enzalutamide 
in the Japanese post-docetaxel CRPC patient population 
showed that enzalutamide was well tolerated when orally 
administered at a dose of 160 mg once daily. PK of enza-
lutamide was dose-proportional in the doses ranging from 
80 to 240 mg and similar to PK data from non-Japanese 
patients. Furthermore, enzalutamide administered orally at 
160 mg once daily had anti-tumor activity in Japanese post-
chemotherapy patients with CRPC, in terms of best overall 
response or tumor-shrinking tendency and PSA response.
However, this study did not achieve radiographic and 
PSA response rates as high as those in AFFIRM. The radio-
graphic response rate by day 85 was 5.3 % in the current 
study versus 28.9 % in AFFIRM. The PSA response rate 
(≥50 % reduction from baseline) was 54.0 % in AFFIRM, 
compared with 28.9 % in this study. Differences between 
the two studies (i.e., patient populations enrolled, study 
setting and design, patient samples in each trial) may 
account for the lower radiographic and PSA response 
rates. As prior docetaxel exposure received by patients in 
1000
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Fig. 2  Comparison of individual enzalutamide Cmax and AUC∞ dur-
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Fig. 3  Individual trough plasma sum of enzalutamide and active 
metabolite concentration versus time plot in the Japanese phase I/II 
and AFFIRM (International, phase III, randomized, double-blind, pla-
cebo-controlled study of enzalutamide in patients with prostate can-
cer who had previously been treated with one or two chemotherapy 
regimens, at least one of which contained docetaxel [14]) studies, up 
to day 169
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this study (median, 198 days; approximately 9–10 cycles) 
was similar to that reported by patients in the AFFIRM 
trial (median, 8.5 cycles) [14], the most important differ-
ence could be that patients in the current study had received 
more hormonal therapy lines prior to enzalutamide com-
pared with those in AFFIRM. With the exclusion of castra-
tion therapies, approximately 90 % of patients in this study 
had received ≥3 prior hormonal therapy lines (i.e., CAB, 
anti-androgen alternative therapy, steroids, and estrogens), 
whereas patients typically received ≤2 lines in AFFIRM. 
This difference may be related to the recommended treat-
ment strategy in Japan, which includes extensive exposure 
to CAB, with bicalutamide 80 mg as the primary ADT and 
further treatment with alternating hormone therapy. This 
observation is also supported by the results of a previous 
surveillance study by the Japan Study Group of Prostate 
Cancer (J-CaP) that considered the current status of endo-
crine therapy for prostate cancer [4]. Of the 3337 patients 
who initially received primary ADT, 2477 patients (74.2 %) 
were given CAB in the J-Cap surveillance [4]. The pattern 
of primary ADT usage was more common in Japan than in 
the United States and primary ADT by CAB was associated 
with better survival than other forms of primary ADT in 
Japanese high-risk patients [2]. Although extensive direct 
comparisons between Japan and the United States are not 
possible, there are some differences between the two coun-
tries in the initial prostate cancer treatment selection and 
outcome [2, 4].
Furthermore, although hormonal treatments have been 
the mainstay of treatment in advanced prostate cancer, 
recent data suggest potential development of cross-resist-
ance after multiple lines of hormonal therapy [21, 22]. In 
the first-in-man enzalutamide phase I/II study in patients in 
the United States, the rate of PSA decline of ≥50 % was 
significantly lower in patients with previous ketoconazole 
treatment versus those without [37 % (95 % CI 25–50 %) 
versus 71 % (95 % CI 60–81 %; p = 0.0007)] [19]. Moreo-
ver, a study of abiraterone acetate plus prednisone showed 
that patients with prior exposure to ketoconazole had a 
lower percentage of PSA decline of ≥50 % compared with 
ketoconazole-naïve patients [23]. In the same study, time to 
PSA progression was shorter in patients with prior ketocon-
azole exposure compared with ketoconazole-naïve patients 
[23]. In addition, there have been several recent reports 
on cross-tolerance between abiraterone plus prednisone 
and enzalutamide. Reports from compassionate use pro-
grams involving heavily pretreated patients with metastatic 
CRPC suggest reduced efficacy for both enzalutamide and 
abiraterone in comparison to the efficacy reported in clini-
cal trials [24, 25]. Furthermore, results of a recent study in 
32 patients suggested a potential effect of androgen receptor 
splice variant-7 on primary treatment resistance, observed 
with abiraterone plus prednisone or enzalutamide [26].
Enzalutamide showed good tolerability in Japanese 
patients, with PK and safety profiles similar to those in non-
Japanese populations included in other enzalutamide stud-
ies. The differences in anti-tumor activity observed in this 
study versus the AFFIRM trial may be attributed to differ-
ences in the study design and patients’ backgrounds in each 
trial. In particular, they may be attributed to differences in 
treatment history prior to starting enzalutamide. This may 
require further investigation to define the optimal timing and 
treatment strategy of enzalutamide for patients with CRPC. 
Particularly in Japan, the influence of sequence for hormone 
treatments, including CAB therapy, should be considered.
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